Results for tag: "Chronic Lymphocytic Leukemia Drug"

Chronic Lymphocytic Leukemia (CLL) is a type of cancer that affects the white blood cells. Treatment for CLL typically involves chemotherapy, radiation, and targeted therapies. Drug therapies for CLL are designed to target the cancer cells and stop them from growing and spreading. These drugs can be used alone or in combination with other treatments. Commonly used drugs for CLL include monoclonal antibodies, such as rituximab and obinutuzumab, and small molecule inhibitors, such as ibrutinib and idelalisib. The CLL drug market is a rapidly growing segment of the leukemia drug market. It is driven by the increasing prevalence of CLL, the development of new drugs, and the increasing demand for personalized treatments. The market is expected to continue to grow in the coming years, as new drugs are developed and approved. Some of the major companies in the CLL drug market include AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Celgene, Gilead Sciences, Novartis, and Roche. Show Less Read more